Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy

Cancer

Volumn 97, Issue 4, 2003, Pages 1127-1133

  Pinover, Wayne H ^a,b   Horwitz, Eric M ^a   Hanlon, Alexandra L ^a   Uzzo, Robert G ^a   Hanks, Gerald E ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b ABINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Prostate specific antigen (PSA); Prostate specific antigen doubling time (PSADT); Prostatic neoplasms; Three dimensional conformal radiation therapy (3DCRT)

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ALGORITHMS; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE PLANNING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT FAILURE;

EID: 0037441773     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11166     Document Type: Article

References (16)

1. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997;15:230-238.
2. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994;74:670-678.
3. Zagars G, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997;44:213-221.
4. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JMG. Overall survival after prostate-specific-antigen detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:629-633.
5. Hanks GE, D'Amico A, Epstein BE, Schultheiss TE. Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys. 1993;27:125-127.
6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1577.
7. American Joint Committee on Cancer. Prostate. In: Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC cancer staging manual. Philadelphia: JB Lippincott, 1997:219-224.
8. Pinover WH, Hanlon A, Lee WR, Kaplan EJ, Hanks GE. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. Cancer. 1996;77:1334-1341.
9. Horwitz EM, Hanlon AL, Pinover WH, Anderson PR, Hanks GE. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with non-metastatic prostate carcinoma by using recursive partitioning techniques. Cancer. 2001;92:1281-1287.
10. International Commission on Radiation Units and Measurements. ICRU report 50: prescribing, recording, and reporting photon beam therapy. Bethesda: International Commission on Radiation Units and Measurements, 1993.
11. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Wilcoxon F. Individual comparison by ranking methods. Biometrics. 1945;1:80-83.
14. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
15. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 1993;72:2638-2643.
16. Shipley WU, Lu JD, Pilepich MV, et al. Does neoadjuvant hormone treatment compromise subsequent androgen suppression in prostate cancer patients who fail initial radiation therapy: a secondary analysis of RTOG 86-10. Int J Radiat Oncol Biol Phys. 2000;48:169.